Lpl Financial LLC Vertex Pharmaceuticals Inc Transaction History

Lpl Financial LLC

$196 Billion
Q2 2024

A detailed history of Lpl Financial LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Lpl Financial LLC holds 209,839 shares of VRTX stock, worth $105 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

209,839

Previous 183,371 14.43%

Holding current value

$105 Million

Previous $76.7 Million 28.32%

% of portfolio

0.05%

Previous 0.04%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$392.81 - $485.53 $10.4 Million - $12.9 Million	26,468 Added 14.43%	209,839 $98.4 Million
Q1 2024 May 10, 2024	BUY	$407.69 - $446.08 $8.05 Million - $8.8 Million	19,735 Added 12.06%	183,371 $76.7 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $3.46 Million - $4.15 Million	-10,101 Reduced 5.81%	163,636 $66.6 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $577,949 - $619,444	1,709 Added 0.99%	173,737 $60.4 Million
Q2 2023 Jul 31, 2023	BUY	$314.42 - $351.91 $1.42 Million - $1.59 Million	4,528 Added 2.7%	172,028 $60.5 Million
Q1 2023 May 10, 2023	BUY	$283.23 - $323.1 $612,060 - $698,219	2,161 Added 1.31%	167,500 $52.8 Million
Q4 2022 Feb 07, 2023	BUY	$285.76 - $321.48 $9.22 Million - $10.4 Million	32,264 Added 24.24%	165,339 $47.7 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $750,568 - $837,457	-2,741 Reduced 2.02%	133,075 $38.5 Million
Q2 2022 Aug 12, 2022	SELL	$234.96 - $292.55 $161,652 - $201,274	-688 Reduced 0.5%	135,816 $38.3 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $3.54 Million - $4.18 Million	16,002 Added 13.28%	136,504 $35.6 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $1.4 Million - $1.77 Million	7,919 Added 7.03%	120,502 $26.5 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $7.09 Million - $7.93 Million	39,081 Added 53.17%	112,583 $20.4 Million
Q2 2021 Aug 13, 2021	BUY	$187.49 - $221.1 $1.89 Million - $2.23 Million	10,071 Added 15.88%	73,502 $14.8 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $4.29 Million - $5 Million	20,735 Added 48.56%	63,431 $13.6 Million
Q4 2020 Feb 12, 2021	SELL	$207.01 - $276.09 $459,355 - $612,643	-2,219 Reduced 4.94%	42,696 $10.1 Million
Q3 2020 Nov 09, 2020	BUY	$255.65 - $303.1 $210,399 - $249,451	823 Added 1.87%	44,915 $12.2 Million
Q2 2020 Aug 13, 2020	BUY	$225.48 - $295.8 $871,254 - $1.14 Million	3,864 Added 9.61%	44,092 $12.8 Million
Q1 2020 May 14, 2020	BUY	$199.77 - $247.81 $567,147 - $703,532	2,839 Added 7.59%	40,228 $9.57 Million
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $178,046 - $239,135	1,068 Added 2.94%	37,389 $8.19 Million
Q3 2019 Nov 13, 2019	SELL	$166.23 - $187.09 $657,107 - $739,566	-3,953 Reduced 9.82%	36,321 $6.15 Million
Q2 2019 Aug 09, 2019	SELL	$164.61 - $190.37 $462,554 - $534,939	-2,810 Reduced 6.52%	40,274 $7.39 Million
Q1 2019 May 08, 2019	SELL	$163.73 - $194.7 $65,000 - $77,295	-397 Reduced 0.91%	43,084 $7.93 Million
Q4 2018 Feb 07, 2019	SELL	$151.91 - $192.21 $116,211 - $147,040	-765 Reduced 1.73%	43,481 $7.21 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $524,323 - $602,505	3,126 Added 7.6%	44,246 $8.53 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $297,268 - $346,718	2,040 Added 5.22%	41,120 $6.99 Million
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $598,213 - $698,954	-3,946 Reduced 9.17%	39,080 $6.37 Million
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $808,167 - $915,722	5,887 Added 15.85%	43,026 $6.45 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $3.47 Million - $3.8 Million	23,396 Added 170.24%	37,139 $5.65 Million
Q2 2017 Aug 14, 2017	BUY	N/A	13,743	13,743 $1.77 Million

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.

Account

Lpl Financial LLC Vertex Pharmaceuticals Inc Transaction History